Glucocorticoid treatment and new‐onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta‐analysis
Authors' conclusion
The prevalence of GIH was 38.6%. Being treated with systemic glucocorticoids for COPD was associated with 2.4 times higher risk of new-onset hyperglycaemia versus no glucocorticoid treatment.
Study context
- Population
- Adults with chronic obstructive pulmonary disease (COPD), with or without diabetes at baseline; databases searched until 9 November 2023
- Participants
- 3,642 adults18 studies
- Comparison
- Systemic glucocorticoids vs no glucocorticoids
- Exposedn = 3,125
- Outcome
- Prevalence of glucocorticoid-induced hyperglycaemia (GIH): proportion of exposed people developing hyperglycaemia (blood glucose above study-specific cut-off)
- Follow-up
- During
Methodological detailsrandom-effects meta-analysis
- Random-effects meta-analysis
Pooled result
As reported in the abstract
Pooled prevalence of glucocorticoid-induced hyperglycaemia (GIH)
Pooled prevalence of glucocorticoid-induced hyperglycaemia (GIH)
38.6%
95% CI 29.9%–47.9%
Heterogeneity I2 (p < 0.010), partially explained by differences in study design
96%
Developed hyperglycaemia
1189
Further pooled results
New-onset hyperglycaemia, systemic glucocorticoids exposed vs non-exposed
- Pooled RR
- 2.39 (95% CI 1.51-3.78)
- 8 studies
Original publication
Glucocorticoid treatment and new‐onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta‐analysis. Diabet Med. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →